Research and development (R&D) spending by BSE 100 companies has grown steadily, rising from 0.89 per cent of revenue in FY20 to 1.32 per cent in FY24, averaging around 1 per cent over the period......
The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for......
Drug major Lupin is recalling 5,60,922 pouches of a birth control product in the US, as per the US Food and Drug Administration (USFDA). Image used for representational purpose only. Photograph:......
Rishad Premji, chairman of IT services major Wipro, saw his compensation for FY23 decline by almost 50 per cent year-on-year, due to a fall in the firm’s profit. Photograph: PTI Photo......
Lupin Pharmaceuticals Inc, the wholly owned subsidiary of Lupin, has entered into an alliance with Cornerstone BioPharma Inc.Cornerstone will be Lupin's promotion partner in the US for its Suprax......